Fig. 4: Overall survival rates at 36 months in Phase 1 and 2 treated patients in key subgroup. | Leukemia

Fig. 4: Overall survival rates at 36 months in Phase 1 and 2 treated patients in key subgroup.

From: Three-year analysis of adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia treated with brexucabtagene autoleucel in ZUMA-3

Fig. 4

Kaplan–Meier estimates of overall survival at Month 36. alloSCT allogeneic stem cell transplant, BM bone marrow, LCI lower confidence interval, MRD minimal residual disease, NE not evaluable, OS overall survival, UCI upper confidence interval.

Back to article page